Research Paper Volume 12, Issue 7 pp 5764—5780

CK1δ as a potential therapeutic target to treat bladder cancer

class="figure-viewer-img"

Figure 1. CK1δ promotes growth of bladder cancer cells. (A, B) Gene expression levels of CSNK1D in tissue samples of normal, carcinoma in situ (CIS), superficial and infiltrating bladder cancer patients obtained from Dyrskjot bladder dataset (A) or Sanchez-Carbayo bladder dataset (B). **P<0.01 compared to normal group. (C) Protein levels of CK1δ in different bladder cancer cell lines analyzed by Western blotting. (D) Control shRNA (shCTRL) or shCK1δ plasmids were transduced into RT112 and T24 cells by lentivirus and the cells were subjected to Western blotting with the indicated antibodies. (E, F) CK1δ knockdown decreases the viability of RT112 (E) and T24 (F) cells at 72 h by MTT assay. Date are represented as mean ± S.D. *P<0.05, ***P<0.001 compared to wild type (WT) cells (n=3).